CoChat
Sign Up
Cited by 260Inflammatory Bowel DiseaseHealth Systems, Economic Evaluations, Quality of LifeStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.

Patient-Reported Outcomes as Primary End Points in Clinical Trials of Inflammatory Bowel Disease

Williet, Nicolas, Sandborn, William J., Peyrin–Biroulet, Laurent·2014·Clinical Gastroenterology and Hepatology
DOI 10.1016/j.cgh.2014.02.016
Open this paper in CoChat — free account

Abstract

The Food and Drug Administration (FDA) is moving from the Crohn's Disease Activity Index to patient-reported outcomes (PROs) and objective measures of disease, such as findings from endoscopy. PROs will become an important aspect of assessing activity of inflammatory bowel disease (IBD) and for labeling specific drugs for this disease. PROs always have been considered in the management of patients with rheumatoid arthritis or multiple sclerosis, and have included measurements of quality of life, disability, or fatigue. Several disease-specific scales have been developed to assess these PROs and commonly are used in clinical trials. Outcomes reported by patients in clinical trials of IBD initially focused on quality of life, measured by the Short-Form 36 questionnaire or disease-specific scales such as the Inflammatory Bowel Disease Questionnaire or its shorter version. Recently considered factors include fatigue, depression and anxiety, and work productivity, as measured by the Functional Assessment Chronic Illness Therapy-Fatigue, the Hospital Anxiety Depression, and the Work Productivity Activity Impairment Questionnaire, respectively. However, few data are available on how treatment affects these factors in patients with IBD. Although disability generally is recognized in patients with IBD, it is not measured. The international IBD disability index currently is being validated. None of the PROs currently used in IBD were developed according to FDA guidance for PRO development. PROs will be a major primary end point of future trials. FDA guidance is needed to develop additional PROs for IBD that can be incorporated into trials, to better compare patients' experience with different therapies.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2014.02.016

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 150 references

Research works printed but not linked: 2

  1. Piper, 1990, Piper fatigue scale available for clinical testing, Oncol Nurs Forum, 17, 661
  2. Masachs, 2007, [Spanish translation, adaptation, and validation of the 32-item questionnaire on quality of life for inflammatory bowel disease(IBDQ-32)], Rev Esp Enferm Dig, 99, 511

Cited by

Sorted by citations

See all 260

Related

Metadata

Authors
Williet, N., Sandborn, W. J., & Peyrin–Biroulet, L.
Affiliations
  • Inserm (FR)
  • University of California San Diego (US)
ORCID
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2014-08
Volume
12
Issue
8
Pages
1246-1256.e6
ISSN
1542-3565 (ISSN-L)
DOI
10.1016/j.cgh.2014.02.016
OpenAlex
W2033081617
Cited by
260
References
150
Citations by year
2026: 9 · 2025: 19 · 2024: 16 · 2023: 14 · 2022: 21 · 2021: 19 · 2020: 26 · 2019: 18 · 2018: 30 · 2017: 24 · 2016: 33 · 2015: 22 · 2014: 8
FWCI
3.83
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Clinical Gastroenterology and Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Optimer Pharmaceuticals
  • Boehringer Ingelheim
  • Shire
  • Bristol-Myers Squibb
  • Pfizer
  • Orexigen Therapeutics
  • UCB Pharma
  • Novartis
  • Roche
  • Gilead Sciences
  • Genentech
  • Merck
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
patient-reported outcomes, inflammatory bowel disease, Crohn's disease, primary endpoint, clinical trial endpoints, CDAI, quality of life, fatigue, anxiety and depression, labor productivity, disability, IBDQ, Short Form-36
MeSH terms
Humans, Surveys and Questionnaires, Inflammatory Bowel Diseases, Treatment Outcome, Drug Monitoring, Patient Satisfaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review